PBAC's latest decision on Tenofovir disoproxil maleate with emtricitabine: Recommended with restriction (2017). Considered for Pre-exposure prophylaxis (PrEP) against HIV infection in adults at medium to high risk of infection.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Adults aged 18 years or older at medium to high risk of HIV infection, as defined by the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) Guidelines, who return a negative HIV test prior to initiating treatment and continue to return negative HIV tests at 3-monthly intervals throughout treatment.
Therapy area
Infectious disease
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
CUA
ICER note
ICER values are redacted (marked as '''''') throughout the document. Table 3 presents cost thresholds at willingness-to-pay levels of $30,000, $60,000, and $90,000 per QALY, but the actual ICER for the proposed price is not disclosed.